traction model, for rationale, on in today. I’d a from components us June revenue highlight today’s commenting States capital everyone. like joining initiated by date. commercial positive the program major model Thank a Thanks you, transformation afternoon, its to United and and Jeannie, start call that recurring to the good sales in to was
current stress additional our VIVEVE near-term II, and international update regulatory to for reported U.S. support before on development opportunity significant a and comments our expansion programs, for that brief indication Viveve’s ongoing LIBERATE-International focus. specifically with in with trial, results the a of call an incontinence I’ll continuing clinical for to continues a company on function and yesterday, questions, opening follow of After represent areas business trial sexual conclude our from urinary the and Viveve’s the the label new overview I’ll
rates As underwent the the of capital that entry physicians traditional by or transformation the to the adoption our the technology commercial to the a represented beginning model shift transition Viveve in reducing recurring to was with U.S. barrier commercial the we a our strategy previously CMRF to increase a under initial of rental-based upfront System The intent XXXX. that to of major reported, revenue at strategic June model. sales cost
This extended required sales. and cost, selling we’ve time amounts and to utilization unit. foresee by per consumable field-based barrier reducing close improving And already adoption greatly expense reducing by spent significantly to rates sales place the reps initial by of and additional system systems increasing customer and per profitability increase upfront sales seen time the
report positive to from customers. physician new pleased We’re response the
in of July company’s first the in the success continued this model history, highest resulted fact, of and transition and productivity level the month In the our has in of August.
customer, annual The quarterly unit monthly and revenue per predictability placements by from a a the revenue establishes of higher and be to multiple basis in on sales improved significantly Introduction will performance rental and projected offset improved unit based unit near on potential on revenue for reduce consumable profitability factors, the it’s the but offers per with greater sustainable placed, lower per selling Viveve revenue term, basis. cost a model future. the for including in growth improved long-term revenue pattern and importantly, program
withdraw under recurring release, of press time guidance associated us lease the transitioning to recognition for to accounting change XX revenue to the in the revenue July impact the over XXXX. revenue our model U.S. our accounting in stated required As and
addition an physician new by our customer the CMRF patients. now suite U.S. In cost to of optimize model services supported of commercial lowering customers adoption upfront for and benefit is of of the increase expanded new success launch Viveve’s the to the designed technology rates, to to enhance
team A dedicated to and who contact is rates. now primary execute offerings coordinate medical and customers assist the specialized practice of will issues, new promote development, product triage utilization higher drive customer and for increase care point and technical with programs or
demonstrations, expert enthusiastic and consultations with new XX procedures practices tips guidelines to University our CMRF to for Viveve University, communication use success that for offered patients. provides customers, patient will expanding the clinical comprehensive inaugural clinical that prospective I on-site training in now Viveve patient lead patients, practices. growing of U Viveve best proudly We the provider believe session program participating. in started and providing say training, in selection their customers XX with today demand training their on can to
to Finally, prevalent unbranded local our of These around also build accounts Viveve connect directly new broader conditions. patients marketing will intimate health model commercial awareness with now who offer targeted procedures. help campaigns, women’s campaigns Viveve consumer physicians geographically includes
massive reporting success and new this commercial of While the look financial model in on transformation from we an months growing this organizational a the perspective, was forward ahead. to
supported model. by our Turning current the to partners change company’s will business without international Sales to to of business. the Viveve international significant continue products distribution be
and feedback remain outside customer our and stress physician technology function to benefits to the enthusiastic patients partners and positive urinary due incontinence. the vaginal Our for treated support sexual laxity, experienced U.S. continue by
customer a specialty the quarter, second partnership in gynecology the Dansys large, clinics health hospitals of and In practices, expanded a distributor, Middle footprint with through also our women’s East well-established urogynecology They in leading medical region. new a medical commercial base we the Gulf and Group. have
lower our result, allow revenue. a which pipelines placements during partners closer and few to QX, made to decision conjunction real-time and recurring model shift sales the them distribution in we also ordering, during in with quarter, shift However, international to international to refill resulted the revenue the our as system
drive us was However, and higher ordering an international improving future. predictability in the towards effort this also important ASPs will to help
mark in regulatory European the Viveve U.S. the and in the quarter for Administration Union. by U.S. potential announced company future opportunity X.X commercial achievement These expands our profitability. next-generation Food the and Drug milestones second and represent of clearances in front, the clearance system and regulatory Viveve significant XXX(k) CE clearance our On
X.X our to future. Our our begins margins has particularly costs gross the impact significantly reduced that to manufacturing on its platform a for and scale revenue expect tips both continue in treatment positive forward, model overall consumable going as recurring system will the next-generation we have
On of health in differentiates other companies us the rigor and from hallmark long a been clinical women’s Viveve intimate side, scientific industry. has the
development their of expanded sexual women’s of lives providing testaments in health in well-being. mission high-quality pursuit labels indications SUI function by our and clinical products proven Our and improve overall programs leading that are enhance to clinically
readout the first double-blind, the to market $X data anticipate advance available in April should a quarter the that billion application sham-controlled year next a results trial important function multicenter ongoing, brought And enrollment support billion our for forward trial estimated program indication, sexual marketing in consumable positive VIVEVE II, total The and completion opportunity look and new is randomized, with this great $X the globally. to in our of U.S. and of commercial to an we U.S.
vaginal sham-controlled robust, a highly by improvement blinded which preceded laxity this we was showed reminder, was published, our I, patients, statistically trial function meaningful and VIVEVE a and in clinically that that on conducted trial As sexual significant. XXX internationally
second the our brought disappointing quarter and Unfortunately, the trial. of LIBERATE-International readout surprising SUI
months at reported and hour six the endpoint, in pad trial, active substantial recently test one demonstrated this the on weight As both post improvement groups control the primary treatment.
However, the active and the group statistical comparison significance. control the not in achieve group did
for XX% secondary pad test the for and weight months active control for the active baseline control post at weight approximately XX% and percentage baseline at improvements six data The data again, from point six change treatment. XX% group of case review end months, August the and X all points for was XX% end for XX-hour based was performed on and The and group. median six the reported one-hour case observed observed months group at was from control. the the on the full A on active pad test in data consistent demonstrated the percentage for change median six was across
incontinence measured XX% groups, at respectively. the six three-day and was for control median in change the episodes XX% by from the months as and baseline reduction active percentage diary, voiding And
quality-of-life the measures questionnaires Additionally, and urodynamic consistent groups. between were both equally
the data. to confounding analyze are continuing We
of the of the duration However, improvement consistency active the improvements these the sham-control effect in treatment that magnitude the due and placebo. both groups to indicate and is unlikely may and
our currently are program. potential we regulatory continue a evaluating As SUI clinical development to options and result,
CMRF A condition. technology to continue SUI. to of from who treatment physicians and independent of from address and indication women and trial efforts suffer contacted worldwide an being feasibility for have noninvasive and by adopted effective an extremely intimate XX-month voice our this of support SUI with results would globally, commercially The these to mild-to-moderate adopt our need who study an approval positive SUI to pursuit the vast estimated that a for continue number Viveve’s durable physicians unmet women million XX have XX regulatory are million us increasing number of their this health of reported replicated KOLs single-session as our
in the moves and April sexual success revenue achieve development programs potential forward the to: our the program. third, and focus are our and of and for new VIVEVE a on through indication SUI one, continuing XXXX, execute of Viveve organizational into prepare growth two, to readout FDA ensure evaluate U.S.; model support and and potentially As the the remainder function II data the for efforts in further in U.S.; advance and year upcoming clinical clearance options number this recurring integral
you. time, to Anita, open call Thank the like to we’d at this questions.
